Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 18 Issue 10, October 2022

A global view of multiple sclerosis genetics, inspired by the Perspective on p613.

Cover design: Philip Patenall.

Comment

  • Responding to increasing concerns around adverse brain health outcomes among former football (soccer) players, the Football Association of England recently announced a trial ban on heading in matches for players aged under 12 years. This is a step in the right direction, but wider interventions to preserve brain health should not be forgotten.

    • William Stewart
    • Alan Carson
    Comment

    Advertisement

Top of page ⤴

Research Highlights

Top of page ⤴

News & Views

  • A phase II trial of the tau antibody semorinemab indicates that it has no clinical benefit in the earliest stages of Alzheimer disease. The repeated finding that antibody-mediated reductions in protein pathology have limited or no clinical benefit indicates that we need to consider more specific or combined therapeutic targets.

    • Francesco Panza
    • Madia Lozupone
    News & Views
Top of page ⤴

Reviews

Top of page ⤴

Perspectives

  • In this Perspective article, the authors outline how studying multiple sclerosis (MS) genetics in ancestrally diverse populations is likely to yield insights that could benefit individuals with MS from all ancestral groups.

    • Benjamin Meir Jacobs
    • Michelle Peter
    • Ruth Dobson
    Perspective
Top of page ⤴

Search

Quick links